PLRX Pliant Therapeutics Inc

Price (delayed)

$1.17

Market cap

$72.45M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.84

Enterprise value

$77.56M

?
Relative Growth: Rel. Growth: 20
Relative Strength: Rel. Strength: 20
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 14

Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Pliant's lead product candidate, PLN-74809, is an oral small-molecule dual ...

Highlights
The company's quick ratio has surged by 53% YoY and by 41% QoQ
Pliant Therapeutics's debt has shrunk by 52% YoY
The equity has contracted by 36% YoY and by 9% from the previous quarter

Key stats

What are the main financial stats of PLRX

PLRX stock price

How has the Pliant Therapeutics stock price performed over time
Intraday
-0.85%
1 week
-6.4%
1 month
-1.68%
1 year
-29.52%
YTD
-4.1%
QTD
-7.14%

Financial performance

How have Pliant Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$119.21M
Net income
-$113.22M
Gross margin
N/A
Net margin
N/A
PLRX's operating income is up by 49% year-on-year and by 24% since the previous quarter
The net income has grown by 48% YoY and by 24% from the previous quarter

Price vs fundamentals

How does PLRX's price correlate with its fundamentals

Growth

What is Pliant Therapeutics's growth rate over time

Valuation

What is Pliant Therapeutics stock price valuation
P/E
N/A
P/B
0.44
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has grown by 49% year-on-year and by 24% since the previous quarter
PLRX's price to book (P/B) is 77% lower than its 5-year quarterly average of 1.9 but 10% higher than its last 4 quarters average of 0.4
The equity has contracted by 36% YoY and by 9% from the previous quarter

Efficiency

How efficient is Pliant Therapeutics business performance
The company's return on invested capital rose by 17% QoQ and by 13% YoY
The ROE is up by 15% since the previous quarter and by 13% year-on-year
Pliant Therapeutics's return on assets has increased by 14% YoY and by 13% QoQ

Dividends

What is PLRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PLRX.

Financial health

How did Pliant Therapeutics financials performed over time
The total liabilities has plunged by 57% YoY and by 15% from the previous quarter
The company's quick ratio has surged by 53% YoY and by 41% QoQ
Pliant Therapeutics's debt is 83% lower than its equity
Pliant Therapeutics's debt has shrunk by 52% YoY
The equity has contracted by 36% YoY and by 9% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.